Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Technosphere Insulin vs Subcutaneous Insulin in Gestational Diabetes
NCT06535789Phase 3Completed
- Sponsor
- Jaeb Center for Health Research
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Technosphere insulin in gestational diabetes mellitus (GDM) (2 arms), sponsored by Jaeb Center for Health Research. Primary endpoint: Post-prandial Area Under the Curve 120 at 3 hours. Started Jun 2025; status: completed.
02
Drugs
Technosphere insulin
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT06535789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535789.